Report cover image

Global Hypogonadism Treatment Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Publisher GlobalInfoResearch
Published Apr 28, 2025
Length 118 Pages
SKU # GFSH19992039

Description

According to our (Global Info Research) latest study, the global Hypogonadism Treatment market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.

hypogonadism usually is treated with testosterone replacement to return testosterone levels to normal. Testosterone can help counter the signs and symptoms of male hypogonadism, such as decreased sexual desire, decreased energy, decreased facial and body hair, and loss of muscle mass and bone density.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report is a detailed and comprehensive analysis for global Hypogonadism Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Hypogonadism Treatment market size and forecasts, in consumption value ($ Million), 2020-2031

Global Hypogonadism Treatment market size and forecasts by region and country, in consumption value ($ Million), 2020-2031

Global Hypogonadism Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031

Global Hypogonadism Treatment market shares of main players, in revenue ($ Million), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Hypogonadism Treatment

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Hypogonadism Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer AG, Abbott Laboratories, Eli Lilly and Company, Sanofi, Merck, Actavis, AbbVie, Teva Pharmaceutical Industries, Endo International, Ferring Holding S.A, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Hypogonadism Treatment market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Testosterone Replacement Treatment
Estrogen Treatment
Progesterone Treatment

Market segment by Application
Hospital Pharmacies
Retail Pharmacies

Market segment by players, this report covers
Bayer AG
Abbott Laboratories
Eli Lilly and Company
Sanofi
Merck
Actavis
AbbVie
Teva Pharmaceutical Industries
Endo International
Ferring Holding S.A
IBSA Pharma
Marius Pharmaceuticals

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Hypogonadism Treatment product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Hypogonadism Treatment, with revenue, gross margin, and global market share of Hypogonadism Treatment from 2020 to 2025.

Chapter 3, the Hypogonadism Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Hypogonadism Treatment market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Hypogonadism Treatment.

Chapter 13, to describe Hypogonadism Treatment research findings and conclusion.

Table of Contents

118 Pages
1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Hypogonadism Treatment by Type
1.3.1 Overview: Global Hypogonadism Treatment Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Hypogonadism Treatment Consumption Value Market Share by Type in 2024
1.3.3 Testosterone Replacement Treatment
1.3.4 Estrogen Treatment
1.3.5 Progesterone Treatment
1.4 Global Hypogonadism Treatment Market by Application
1.4.1 Overview: Global Hypogonadism Treatment Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital Pharmacies
1.4.3 Retail Pharmacies
1.5 Global Hypogonadism Treatment Market Size & Forecast
1.6 Global Hypogonadism Treatment Market Size and Forecast by Region
1.6.1 Global Hypogonadism Treatment Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Hypogonadism Treatment Market Size by Region, (2020-2031)
1.6.3 North America Hypogonadism Treatment Market Size and Prospect (2020-2031)
1.6.4 Europe Hypogonadism Treatment Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Hypogonadism Treatment Market Size and Prospect (2020-2031)
1.6.6 South America Hypogonadism Treatment Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Hypogonadism Treatment Market Size and Prospect (2020-2031)
2 Company Profiles
2.1 Bayer AG
2.1.1 Bayer AG Details
2.1.2 Bayer AG Major Business
2.1.3 Bayer AG Hypogonadism Treatment Product and Solutions
2.1.4 Bayer AG Hypogonadism Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Bayer AG Recent Developments and Future Plans
2.2 Abbott Laboratories
2.2.1 Abbott Laboratories Details
2.2.2 Abbott Laboratories Major Business
2.2.3 Abbott Laboratories Hypogonadism Treatment Product and Solutions
2.2.4 Abbott Laboratories Hypogonadism Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Abbott Laboratories Recent Developments and Future Plans
2.3 Eli Lilly and Company
2.3.1 Eli Lilly and Company Details
2.3.2 Eli Lilly and Company Major Business
2.3.3 Eli Lilly and Company Hypogonadism Treatment Product and Solutions
2.3.4 Eli Lilly and Company Hypogonadism Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Eli Lilly and Company Recent Developments and Future Plans
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business
2.4.3 Sanofi Hypogonadism Treatment Product and Solutions
2.4.4 Sanofi Hypogonadism Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Sanofi Recent Developments and Future Plans
2.5 Merck
2.5.1 Merck Details
2.5.2 Merck Major Business
2.5.3 Merck Hypogonadism Treatment Product and Solutions
2.5.4 Merck Hypogonadism Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Merck Recent Developments and Future Plans
2.6 Actavis
2.6.1 Actavis Details
2.6.2 Actavis Major Business
2.6.3 Actavis Hypogonadism Treatment Product and Solutions
2.6.4 Actavis Hypogonadism Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Actavis Recent Developments and Future Plans
2.7 AbbVie
2.7.1 AbbVie Details
2.7.2 AbbVie Major Business
2.7.3 AbbVie Hypogonadism Treatment Product and Solutions
2.7.4 AbbVie Hypogonadism Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 AbbVie Recent Developments and Future Plans
2.8 Teva Pharmaceutical Industries
2.8.1 Teva Pharmaceutical Industries Details
2.8.2 Teva Pharmaceutical Industries Major Business
2.8.3 Teva Pharmaceutical Industries Hypogonadism Treatment Product and Solutions
2.8.4 Teva Pharmaceutical Industries Hypogonadism Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
2.9 Endo International
2.9.1 Endo International Details
2.9.2 Endo International Major Business
2.9.3 Endo International Hypogonadism Treatment Product and Solutions
2.9.4 Endo International Hypogonadism Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Endo International Recent Developments and Future Plans
2.10 Ferring Holding S.A
2.10.1 Ferring Holding S.A Details
2.10.2 Ferring Holding S.A Major Business
2.10.3 Ferring Holding S.A Hypogonadism Treatment Product and Solutions
2.10.4 Ferring Holding S.A Hypogonadism Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Ferring Holding S.A Recent Developments and Future Plans
2.11 IBSA Pharma
2.11.1 IBSA Pharma Details
2.11.2 IBSA Pharma Major Business
2.11.3 IBSA Pharma Hypogonadism Treatment Product and Solutions
2.11.4 IBSA Pharma Hypogonadism Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 IBSA Pharma Recent Developments and Future Plans
2.12 Marius Pharmaceuticals
2.12.1 Marius Pharmaceuticals Details
2.12.2 Marius Pharmaceuticals Major Business
2.12.3 Marius Pharmaceuticals Hypogonadism Treatment Product and Solutions
2.12.4 Marius Pharmaceuticals Hypogonadism Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Marius Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Hypogonadism Treatment Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Hypogonadism Treatment by Company Revenue
3.2.2 Top 3 Hypogonadism Treatment Players Market Share in 2024
3.2.3 Top 6 Hypogonadism Treatment Players Market Share in 2024
3.3 Hypogonadism Treatment Market: Overall Company Footprint Analysis
3.3.1 Hypogonadism Treatment Market: Region Footprint
3.3.2 Hypogonadism Treatment Market: Company Product Type Footprint
3.3.3 Hypogonadism Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Hypogonadism Treatment Consumption Value and Market Share by Type (2020-2025)
4.2 Global Hypogonadism Treatment Market Forecast by Type (2026-2031)
5 Market Size Segment by Application
5.1 Global Hypogonadism Treatment Consumption Value Market Share by Application (2020-2025)
5.2 Global Hypogonadism Treatment Market Forecast by Application (2026-2031)
6 North America
6.1 North America Hypogonadism Treatment Consumption Value by Type (2020-2031)
6.2 North America Hypogonadism Treatment Market Size by Application (2020-2031)
6.3 North America Hypogonadism Treatment Market Size by Country
6.3.1 North America Hypogonadism Treatment Consumption Value by Country (2020-2031)
6.3.2 United States Hypogonadism Treatment Market Size and Forecast (2020-2031)
6.3.3 Canada Hypogonadism Treatment Market Size and Forecast (2020-2031)
6.3.4 Mexico Hypogonadism Treatment Market Size and Forecast (2020-2031)
7 Europe
7.1 Europe Hypogonadism Treatment Consumption Value by Type (2020-2031)
7.2 Europe Hypogonadism Treatment Consumption Value by Application (2020-2031)
7.3 Europe Hypogonadism Treatment Market Size by Country
7.3.1 Europe Hypogonadism Treatment Consumption Value by Country (2020-2031)
7.3.2 Germany Hypogonadism Treatment Market Size and Forecast (2020-2031)
7.3.3 France Hypogonadism Treatment Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Hypogonadism Treatment Market Size and Forecast (2020-2031)
7.3.5 Russia Hypogonadism Treatment Market Size and Forecast (2020-2031)
7.3.6 Italy Hypogonadism Treatment Market Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Hypogonadism Treatment Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Hypogonadism Treatment Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Hypogonadism Treatment Market Size by Region
8.3.1 Asia-Pacific Hypogonadism Treatment Consumption Value by Region (2020-2031)
8.3.2 China Hypogonadism Treatment Market Size and Forecast (2020-2031)
8.3.3 Japan Hypogonadism Treatment Market Size and Forecast (2020-2031)
8.3.4 South Korea Hypogonadism Treatment Market Size and Forecast (2020-2031)
8.3.5 India Hypogonadism Treatment Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Hypogonadism Treatment Market Size and Forecast (2020-2031)
8.3.7 Australia Hypogonadism Treatment Market Size and Forecast (2020-2031)
9 South America
9.1 South America Hypogonadism Treatment Consumption Value by Type (2020-2031)
9.2 South America Hypogonadism Treatment Consumption Value by Application (2020-2031)
9.3 South America Hypogonadism Treatment Market Size by Country
9.3.1 South America Hypogonadism Treatment Consumption Value by Country (2020-2031)
9.3.2 Brazil Hypogonadism Treatment Market Size and Forecast (2020-2031)
9.3.3 Argentina Hypogonadism Treatment Market Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Hypogonadism Treatment Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Hypogonadism Treatment Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Hypogonadism Treatment Market Size by Country
10.3.1 Middle East & Africa Hypogonadism Treatment Consumption Value by Country (2020-2031)
10.3.2 Turkey Hypogonadism Treatment Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Hypogonadism Treatment Market Size and Forecast (2020-2031)
10.3.4 UAE Hypogonadism Treatment Market Size and Forecast (2020-2031)
11 Market Dynamics
11.1 Hypogonadism Treatment Market Drivers
11.2 Hypogonadism Treatment Market Restraints
11.3 Hypogonadism Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Hypogonadism Treatment Industry Chain
12.2 Hypogonadism Treatment Upstream Analysis
12.3 Hypogonadism Treatment Midstream Analysis
12.4 Hypogonadism Treatment Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.